Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study
- PMID: 23922062
- PMCID: PMC3788608
- DOI: 10.7326/0003-4819-159-3-201308060-00006
Mucosal healing and risk for lymphoproliferative malignancy in celiac disease: a population-based cohort study
Abstract
Background: Celiac disease (CD) is associated with an increased risk for lymphoproliferative malignancy (LPM). Whether this risk is affected by the results of follow-up intestinal biopsy, performed to document mucosal healing, is unknown.
Objective: To examine the association between mucosal healing in CD and subsequent LPM.
Design: Population-based cohort study.
Setting: 28 pathology departments in Sweden.
Patients: 7625 patients with CD who had follow-up biopsy after initial diagnosis.
Measurements: The risk for LPM was compared with that of the general population by using expected rates. The rate of LPM in patients with persistent villous atrophy was compared with that of those with mucosal healing by using Cox regression.
Results: Among 7625 patients with CD and follow-up biopsy, 3308 (43%) had persistent villous atrophy. The overall risk for LPM was higher than that in the general population (standardized incidence ratio [SIR], 2.81 [95% CI, 2.10 to 3.67]) and was greater among patients with persistent villous atrophy (SIR, 3.78 [CI, 2.71 to 5.12]) than among those with mucosal healing (SIR, 1.50 [CI, 0.77 to 2.62]). Persistent villous atrophy compared with mucosal healing was associated with an increased risk for LPM (hazard ratio [HR], 2.26 [CI, 1.18 to 4.34]). The risk for T-cell lymphoma was increased (HR, 3.51 [CI, 0.75 to 16.34]) but not for B-cell lymphoma (HR, 0.97 [CI, 0.21 to 4.49]).
Limitation: No data on dietary adherence.
Conclusion: Increased risk for LPM in CD is associated with the follow-up biopsy results, with a higher risk among patients with persistent villous atrophy. Follow-up biopsy may effectively stratify patients with CD by risk for subsequent LPM.
Conflict of interest statement
All authors declare that they have no conflicts of interest and nothing to declare.
Summary for patients in
-
Summaries for patients. Risk for lymphoma and the results of follow-up gut biopsies in patients with celiac disease.Ann Intern Med. 2013 Aug 6;159(3):I-20. doi: 10.7326/0003-4819-159-3-201308060-00002. Ann Intern Med. 2013. PMID: 23922078 No abstract available.
Similar articles
-
Does celiac disease influence survival in lymphoproliferative malignancy?Eur J Epidemiol. 2013 Jun;28(6):475-83. doi: 10.1007/s10654-013-9789-8. Epub 2013 Mar 5. Eur J Epidemiol. 2013. PMID: 23463575 Free PMC article.
-
Mucosal healing and mortality in coeliac disease.Aliment Pharmacol Ther. 2013 Feb;37(3):332-9. doi: 10.1111/apt.12164. Epub 2012 Nov 28. Aliment Pharmacol Ther. 2013. PMID: 23190299 Free PMC article.
-
Mucosal healing and the risk of ischemic heart disease or atrial fibrillation in patients with celiac disease; a population-based study.PLoS One. 2015 Jan 30;10(1):e0117529. doi: 10.1371/journal.pone.0117529. eCollection 2015. PLoS One. 2015. PMID: 25635403 Free PMC article.
-
Tests for Serum Transglutaminase and Endomysial Antibodies Do Not Detect Most Patients With Celiac Disease and Persistent Villous Atrophy on Gluten-free Diets: a Meta-analysis.Gastroenterology. 2017 Sep;153(3):689-701.e1. doi: 10.1053/j.gastro.2017.05.015. Epub 2017 May 22. Gastroenterology. 2017. PMID: 28545781 Free PMC article. Review.
-
Histopathology of celiac disease.Gastrointest Endosc Clin N Am. 2012 Oct;22(4):679-94. doi: 10.1016/j.giec.2012.07.001. Epub 2012 Aug 29. Gastrointest Endosc Clin N Am. 2012. PMID: 23083986 Review.
Cited by
-
A Case of Immune Checkpoint Inhibitor-Induced Duodenitis.ACG Case Rep J. 2024 Oct 14;11(10):e01539. doi: 10.14309/crj.0000000000001539. eCollection 2024 Oct. ACG Case Rep J. 2024. PMID: 39421733 Free PMC article.
-
Digesting gluten with oral endopeptidases to improve the management of celiac disease.World J Gastroenterol. 2024 Jul 14;30(26):3201-3205. doi: 10.3748/wjg.v30.i26.3201. World J Gastroenterol. 2024. PMID: 39086640 Free PMC article.
-
Evolution in coeliac disease diagnosis and management.JGH Open. 2024 Jul 2;8(7):e13107. doi: 10.1002/jgh3.13107. eCollection 2024 Jul. JGH Open. 2024. PMID: 38957478 Free PMC article. Review.
-
Celiac Disease, Gluten Sensitivity, and Diet Management.Curr Gastroenterol Rep. 2024 Aug;26(8):191-199. doi: 10.1007/s11894-024-00931-x. Epub 2024 Jun 12. Curr Gastroenterol Rep. 2024. PMID: 38865028 Review.
-
Exploring factors influencing quality of life variability among individuals with coeliac disease: an online survey.BMJ Open Gastroenterol. 2024 Jun 2;11(1):e001395. doi: 10.1136/bmjgast-2024-001395. BMJ Open Gastroenterol. 2024. PMID: 38830687 Free PMC article.
References
-
- Green PH, Cellier C. Celiac disease. N Engl J Med. 2007;357(17):1731–43. - PubMed
-
- Mustalahti K, Catassi C, Reunanen A, Fabiani E, Heier M, McMillan S, et al. The prevalence of celiac disease in Europe: results of a centralized, international mass screening project. Ann Med. 2010;42(8):587–95. - PubMed
-
- Catassi C, Kryszak D, Bhatti B, Sturgeon C, Helzlsouer K, Clipp SL, et al. Natural history of celiac disease autoimmunity in a USA cohort followed since 1974. Ann Med. 2010;42(7):530–8. - PubMed
-
- Elfstrom P, Granath F, Ekstrom Smedby K, Montgomery SM, Askling J, Ekbom A, et al. Risk of lymphoproliferative malignancy in relation to small intestinal histopathology among patients with celiac disease. J Natl Cancer Inst. 2011;103(5):436–44. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical